Tech Company Financing Transactions

Escient Pharmaceuticals Funding Round

On 9/15/2020, Escient Pharmaceuticals raised $77.5 million in Series B investment from Cowen Capital Partners, Sanofi-Genzyme BioVentures and 5AM Ventures.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

10578 Science Center Dr. 250
San Diego, CA 92121
USA

Phone

(858) 617-8220

Website

www.escientpharma.com

Email Address

[email protected]

Overview

Escient Pharmaceuticals. We are a privately held biotechnology company that is advancing first-in-class G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Alain Baron

        

Chief Scientific Officer

Marcus Boehm

        

Vice President

Richard Pittner

        

Vice President

Kristin Taylor

        

Vice President

Gregg Timony

        

VP - Bus. Development

William Hodder

        

VP - R & D

Esther Martinborough

        

Browse more venture capital transactions:

Prev: 9/15/2020: Attralus venture capital transaction
Next: 9/15/2020: Spine Align venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary